Quanterix Corp

Quanterix Corp

QTRX · NASDAQ · Healthcare / Medical Devices

2.93USD+0.07 (+2.45%)

Price History

Full chart

Market Stats

Previous Close2.86
Open2.90
Day Range2.78 – 3.04
52-Week Range2.15 – 8.77
Volume394.29K
Market Cap166.47M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.62
Dividend Yield0.00%
Beta1.04
50-Day Avg3.10
200-Day Avg4.34

About

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Everett V. Cunningham
  • Employees450
  • HeadquartersBuilding 1, Billerica, MA, United States, 01821, USA
  • Websitehttps://www.quanterix.com

Leadership

  • Mr. William P. DonnellyExecutive Chair · b. 1962
  • Dr. David R. Walt Ph.D.Co-Founder & Chairman of Scientific Advisory Board · b. 1953
  • Mr. Everett V. CunninghamPresident, CEO & Director · b. 1966
  • Mr. Jason FaesslerCFO & Treasurer
  • Mr. Anthony CatalanoChief Operating Officer
  • Dr. Michael Miller Ph.D.Chief Technology & Products Officer · b. 1964
  • Joshua YoungHead of Investor Relations
  • Mr. Daniel S. Char J.D.Chief Legal Officer & Corporate Secretary · b. 1961
  • Ms. Erica BellChief People Officer · b. 1973
  • Mr. Naren BhatChief Strategy Officer

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue12.18M17.59M22.87M37.63M56.73M86.38M110.56M105.52M121.14M135.44M138.65M
Growth (%)-+44.38%+30.08%+64.52%+50.76%+52.25%+27.99%-4.55%+14.80%+11.80%+2.38%
Cost of Revenue6.46M9.84M12.89M19.65M29.90M38.20M48.83M60.16M48.14M54.32M73.94M
Gross Profit5.71M7.75M9.99M17.98M26.84M48.18M61.73M45.36M73.00M81.12M64.72M
Gross Margin46.92%44.06%43.66%47.79%47.30%55.78%55.83%42.99%60.26%59.89%46.67%
Operating Expense20.24M29.46M35.99M49.53M68.44M79.77M120.31M149.63M118.99M133.74M174.53M
Operating Income-14.52M-21.71M-26.00M-31.55M-41.60M-31.58M-58.59M-104.26M-45.99M-52.62M-109.81M
Operating Margin-119.24%-123.46%-113.69%-83.84%-73.32%-36.57%-52.99%-98.81%-37.97%-38.85%-79.20%
EBITDA-14.48M-21.43M-25.59M-30.20M-38.59M-27.27M-53.73M-67.89M-36.37M-29.74M-93.35M
EBITDA Margin-118.87%-121.87%-111.86%-80.25%-68.02%-31.57%-48.60%-64.34%-30.03%-21.96%-67.32%
Net Income-15.94M-23.17M-27.02M-31.05M-40.80M-31.53M-57.69M-99.57M-28.35M-38.53M-107.15M
Net Income Margin-130.89%-131.78%-118.12%-82.50%-71.91%-36.50%-52.18%-94.36%-23.41%-28.45%-77.28%
R&D10.08M16.99M16.30M15.29M16.19M20.17M27.98M26.81M26.06M31.08M35.92M
R&D as % of Total Revenue82.78%96.63%71.28%40.64%28.54%23.36%25.31%25.41%21.52%22.95%25.91%
Interest Expense1.04M1.30M952.00K46.00K627.00K273.00K403.00K5.13M15.84M--
Interest Expense % of Total Revenue8.54%7.38%4.16%0.12%1.11%0.32%0.36%4.86%13.08%--

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.35M37.12M91.78M67.63M169.95M271.05M506.51M433.58M428.57M406.53M418.77M
Total Liabilities22.55M23.64M25.91M26.07M41.29M64.92M65.56M75.65M78.61M76.50M123.04M
Total Equity-15.20M13.48M65.87M41.56M128.66M206.13M440.95M357.93M349.96M330.04M295.73M
Cash2.32M29.67M79.68M45.43M109.16M181.58M396.46M338.74M174.42M56.71M29.84M
Total Debt15.27M13.04M9.38M8.09M7.66M30.80M21.89M44.10M41.46M37.37M37.24M
Net Debt7.40M-19.43M-70.30M-37.81M-101.49M-150.79M-374.57M-294.64M-132.96M-19.34M7.40M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.52M-17.74M-22.11M-28.72M-26.19M-23.36M-47.91M-48.27M-18.90M-35.16M-77.24M
Investing Cash Flow-554.00K-826.00K-1.13M-5.45M-25.38M-626.00K-6.34M-11.21M-148.40M-82.27M50.23M
Financing Cash Flow11.70M45.92M73.25M-78.00K116.20M96.24M270.80M2.31M2.69M456.00K-708.00K
Capital Expenditure597.00K526.00K1.13M1.52M10.85M3.93M13.62M11.73M3.79M3.37M2.61M
Free Cash Flow-13.11M-18.27M-23.24M-30.24M-37.03M-27.30M-61.52M-60.00M-22.69M-38.53M-79.85M
FCF to OCF104.77%102.96%105.12%105.29%141.42%116.82%128.42%124.29%120.04%109.58%103.38%

Earnings

Report DateJul 21, 2017Dec 15, 2017Mar 14, 2018May 15, 2018Aug 10, 2018Nov 7, 2018Mar 7, 2019May 10, 2019Aug 6, 2019Nov 8, 2019Mar 9, 2020May 7, 2020Aug 4, 2020Nov 5, 2020Mar 2, 2021May 5, 2021Aug 5, 2021Nov 4, 2021Mar 1, 2022May 10, 2022Aug 8, 2022Nov 8, 2022Mar 6, 2023May 9, 2023Aug 7, 2023Nov 6, 2023Feb 29, 2024May 7, 2024Aug 8, 2024Dec 26, 2024Feb 26, 2025May 12, 2025Aug 7, 2025Nov 10, 2025Mar 3, 2026May 6, 2026Aug 10, 2026Nov 9, 2026
EPS Estimate0.000.00-0.32-0.27-0.29-0.31-0.31-0.40-0.42-0.44-0.43-0.41-0.50-0.42-0.33-0.34-0.33-0.33-0.66-0.61-0.59-0.44-0.47-0.38-0.41-0.40-0.32-0.31-0.26-0.23-0.25-0.43-0.41-0.53-0.43-0.62-0.56-0.49
EPS Actual-0.37-0.75-1.06-0.33-0.34-0.35-0.39-0.42-0.46-0.34-0.39-0.38-0.41-0.26-0.31-0.29-0.31-0.43-0.55-0.49-0.67-0.40-0.50-0.14-0.13-0.21-0.33-0.26-0.25-0.22-0.30-0.53-0.47-0.73-0.470.16-0.45-
Surprise---231.25%-22.22%-17.24%-12.90%-25.81%-5.00%-9.52%22.73%9.30%7.32%18.00%38.10%6.06%14.71%6.06%-30.30%16.67%19.67%-13.56%9.09%-6.38%63.16%68.29%47.50%-3.13%16.13%3.85%4.35%-18.11%-23.26%-14.63%-37.74%-8.75%125.81%19.64%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap166.47M
Enterprise Value89.30M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.09
Price / Book0.63
EPS-2.62
Book Value5.03
Revenue (TTM)153.41M
Gross Profit (TTM)68.36M
EBITDA-70.50M
Profit Margin-80.25%
Operating Margin-68.37%
Return on Equity-46.49%
Return on Assets-16.67%
Shares Outstanding47.29M
Shares Float38.01M
Beta1.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 3.00
  • Strong Buy
    1
  • Buy
    1
  • Hold
    2

Ownership Breakdown

Institutions
71.25%
Insiders
6.33%
Retail / Other
22.42%

Top Institutional Holders

  • Arnhold & S. Bleichroeder Advisers, LLC
    5.51M11.64%
  • Ameriprise Financial Inc
    3.54M7.49%
  • Blue Water Life Science Advisors, LLC
    3.47M7.35%
  • BlackRock Inc
    3.28M6.93%
  • Portolan Capital Management, LLC
    2.95M6.23%
  • Invenomic Capital Management, LP
    1.93M4.09%
  • Vanguard Capital Management, LLC
    1.78M3.77%
  • Geode Capital Management, LLC
    994.76K2.10%
  • State Street Corp
    898.28K1.90%
  • Marshall Wace Asset Management Ltd
    622.38K1.32%
  • Morgan Stanley - Brokerage Accounts
    607.86K1.29%
  • Vanguard Portfolio Management, LLC
    576.60K1.22%
  • Tikvah Management LLC
    571.55K1.21%

Top Fund Holders

  • First Eagle Small Cap Opportunity I
    2.13M4.51%
  • Strategic Advisers U.S. Total Stock
    1.44M3.05%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.25M2.65%
  • iShares Russell 2000 ETF
    1.11M2.34%
  • Invenomic Institutional
    771.54K1.63%
  • Columbia Small Cap Value Discv A
    689.24K1.46%
  • Fidelity Small Cap Index
    462.80K0.98%